← Leaderboards
Yi Sun
University Of Michigan At Ann Arbor
$9,791,676
Attributed
$9,791,676
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$9,791,676 · 7
By mechanism
R01$9,035,810 · 4
R21$679,775 · 2
R03$76,091 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Weiping Zou$38,970,401
- Andrzej A Dlugosz$18,965,035
- Marina Pasca Di Magliano$14,782,555
- Elizabeth R Lawlor$9,932,316
- Craig J Galban$12,293,457
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisUbiquitin-Protein LigaseGenesIn VitroFutureCancer TherapyInhibitor/AntagonistMalignant NeoplasmsIn VivoCullin ProteinsValidationAntineoplastic AgentsProteinsSmall Interfering RnaCarcinogenesisMouse ModelInnovationPathway InteractionsTumorGrowthSmall MoleculeTranscription Factor Ap-1Rbx1 GeneTissues
Grant awards (36)
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2$357,081
R01 · FY2019 · CA · contact PI
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2$368,125
R01 · FY2018 · CA · contact PI
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2$368,125
R01 · FY2017 · CA · contact PI
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis$322,663
R01 · FY2017 · CA · contact PI
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2$368,125
R01 · FY2016 · CA · contact PI
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis$322,663
R01 · FY2016 · CA · contact PI
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target$322,663
R01 · FY2015 · CA · contact PI
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis$322,663
R01 · FY2015 · CA · contact PI
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis$268,009
R01 · FY2015 · CA · contact PI
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target$312,983
R01 · FY2014 · CA · contact PI
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis$312,983
R01 · FY2014 · CA · contact PI
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis$259,968
R01 · FY2014 · CA · contact PI
Anti-pancreatic tumorigenesis by inactivation of SAG/RBX2 E3 ubiquitin ligase$164,034
R21 · FY2014 · CA · contact PI
Role of SAG/RBX2 E3 Ubiquitin Ligase in Skin Carcinogenesis$322,663
R01 · FY2013 · CA · contact PI
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target$303,303
R01 · FY2013 · CA · contact PI
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis$251,929
R01 · FY2013 · CA · contact PI
Anti-pancreatic tumorigenesis by inactivation of SAG/RBX2 E3 ubiquitin ligase$202,928
R21 · FY2013 · CA · contact PI
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target$322,663
R01 · FY2012 · CA · contact PI
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis$268,009
R01 · FY2012 · CA · contact PI
Mechanistic validation of SCF E3 ligase as a cancer and radiosensitizing target$314,127
R01 · FY2011 · CA · contact PI
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesis$267,435
R01 · FY2011 · CA · contact PI
Luciferase-based screening for p53 conformational activators$37,466
R03 · FY2011 · DA · contact PI
SAG E3 ubiquitin ligase in angiogenesis & carcinogenesis$298,007
R01 · FY2010 · CA · contact PI
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis$261,886
R01 · FY2010 · CA · contact PI
Luciferase-based screening for p53 conformational activators$38,625
R03 · FY2010 · DA · contact PI
SAG E3 ubiquitin ligase in angiogenesis & carcinogenesis$298,007
R01 · FY2009 · CA · contact PI
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis$260,972
R01 · FY2009 · CA · contact PI
Mechanism of SAG apoptosis protection under hypoxia$286,517
R01 · FY2008 · CA · contact PI
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis$261,394
R01 · FY2008 · CA · contact PI
Mechanism of SAG apoptosis protection under hypoxia$286,517
R01 · FY2007 · CA · contact PI
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis$261,886
R01 · FY2007 · CA · contact PI
Substrates of SAG-SCF E3 ligase regulate hypoxia response$168,255
R21 · FY2007 · CA · contact PI
Mechanism of SAG apoptosis protection under hypoxia$295,074
R01 · FY2006 · CA · contact PI
Mechanisms of SAG Inhibition of Carcinogenesis & Apoptosis$269,707
R01 · FY2006 · CA · contact PI
Substrates of SAG-SCF E3 ligase regulate hypoxia response$144,558
R21 · FY2006 · CA · contact PI
Mechanism of SAG apoptosis protection under hypoxia$299,663
R01 · FY2005 · CA